儿童B细胞前体急性淋巴细胞白血病中IKZF1基因组变异异质性与复发风险
在688例接受St. Jude Total Therapy XV和16研究的儿童B-ALL患者中,115例(16.7%)存在IKZF1变异,最常见于BCR::ABL1(78%)和CRLF2重排的BCR::ABL1样B-ALL(70%)。IKZF1变异患者5年累积复发率为14.8±3.3%,无变异者为5.0±0.9%(P<0.0001);外显子4-7缺失、基因组IKZF1plus等为独立不良预后因素。
要点
- IKZF1变异见于16.7%儿童B-ALL,常见于BCR::ABL1和CRLF2重排亚型。
- IKZF1变异者5年累积复发率14.8±3.3%,无变异者5.0±0.9%。
- 外显子4-7缺失和基因组IKZF1plus是独立不良预后因素。
核心结论
- IKZF1变异类型结合B-ALL亚型可为风险分层和预测治疗反应提供信息。
研究设计与样本
- 研究纳入St. Jude Total Therapy XV和16研究中的688例儿童B-ALL患者,采用转录组和基因组测序及SNP微阵列分析确定亚型和基因组变异。
主要发现
- 115例(16.7%)患者检出IKZF1变异,最常见于BCR::ABL1(78%)和CRLF2重排的BCR::ABL1样B-ALL(70%)。
- IKZF1变异患者5年累积复发率为14.8±3.3%,无任何IKZF1变异者为5.0±0.9%(P<0.0001)。
- 多变量分析中,外显子4-7缺失(P=0.0002)、基因组IKZF1plus伴任何IKZF1缺失(P=0.006)或伴局灶性IKZF1缺失(P=0.0007)及不良基因组亚型(P<0.005)为独立不良预后因素。
- 基因组IKZF1plus和外显子4-7缺失与不良结局的关联在独立队列中得到验证。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genomic alterations of IKZF1 are common and associated with adverse clinical features in B-progenitor acute lymphoblastic leukemia (B-ALL). The relationship between the type of IKZF1 alteration, B-ALL genomic subtype and outcome are incompletely understood. B-ALL subtype and genomic alterations were determined using transcriptome and genomic sequencing, and SNP microarray analysis in 688 pediatric patients with B-ALL in the St. Jude Total Therapy XV and 16 studies. IKZF1 alterations were identified in 115 (16.7%) patients, most commonly in BCR::ABL1 (78%) and CRLF2-rearranged, BCR::ABL1-like B-ALL (70%). These alterations were associated with 5-year cumulative incidence of relapse (CIR) of 14.8 ± 3.3% compared to 5.0 ± 0.9% for patients without any IKZF1 alteration (P < 0.0001). In separate multivariable analyses adjusting for genetic subtype groups and other factors, IKZF1 deletions of exons 4-7 (P = 0.0002), genomic IKZF1plus with any IKZF1 deletion (P = 0.006) or with focal IKZF1 deletion (P = 0.0007), and unfavorable genomic subtypes (P < 0.005) were independently adverse prognostic factors. Associations of genomic IKZF1plus and exon 4-7 deletions with adverse outcomes were confirmed in an independent cohort. The type of IKZF1 alteration, together with the subtype, are informative for risk stratification and to predict response in patients with B-ALL.
引用
- Wang'ondu RW, Ashcraft E, Chang TC, et al. Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia. Leukemia. 2025. PMID: 40360879. doi:10.1038/s41375-025-02633-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。